Wire · opportunities
First Relapse in Myeloma: Making Sense of New Options
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
Multiple new treatments have emerged for first relapse multiple myeloma, including teclistamab, talquetamab, mezigdomide, iberdomide, and cilta-cel, each showing progression-free survival benefits but with different patient profiles and toxicity risks.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
You must weigh treatment efficacy against tolerance and patient refractory status due to new therapies' varying risks and benefits. Your choice in first relapse myeloma now shapes care duration and morbidity, so prioritise agents with manageable side effects for broader market access.
◆ Coverage
1 source · 24 Oct 2026
◆ Related on Wire
◆ Topics